Johnson & Johnson's (JNJ.US) FGFR inhibitor "erdafitinib" has been approved for marketing in China.

On January 13th, Johnson & Johnson (JNJ.US) announced that its innovative treatment drug Erdafitinib tablets (trade name: Boke) has officially been approved by the National Medical Products Administration for the treatment of adult patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who carry susceptible FGFR3 gene mutations and have previously undergone at least one-line treatment with an anti-PD-1 or anti-PD-L1 agent and experienced disease progression. Ms. Cherry Huang, President of Innovative Pharmaceuticals, Johnson & Johnson China, stated: "Erdafitinib has demonstrated significant benefits and broad application prospects for late-stage bladder cancer patients through targeted therapy, highlighting the importance of FGFR gene testing in the diagnosis and treatment of metastatic urothelial carcinoma. As an important milestone in this field, the approval of this drug demonstrates Johnson & Johnson's ongoing commitment to advancing precision treatment in the field of oncology and improving patient survival benefits in the long term. In the future, we will continue to focus on areas with significant unmet medical needs, leading medicine into the future with science, fully promoting the full lifecycle management of cancer, and striving to make cancer a controllable and curable chronic disease."